Inconsistencies in opioid equianalgesic ratios: Clinical and research implications

Journal of Pain and Palliative Care Pharmacotherapy

Volumn 22, Issue 4, 2008, Pages 282-290

  O'Bryant, Cindy L ^a   Linnebur, Sunny A ^a   Yamashita, Traci E ^b   Kutner, Jean S ^b  

^a School of Pharmacy

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Equianalgesic ratios; Fentanyl; Methadone; Opioids; Oxycodone; Pain

Indexed keywords

FENTANYL; LONG ACTING DRUG; METHADONE; MORPHINE; OPIATE DERIVATIVE; OXYCODONE;

ADVANCED CANCER; ANALGESIA; ARTICLE; CANCER PAIN; CANCER PATIENT; DOSE CALCULATION; HUMAN;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ADULT; ANALGESICS, OPIOID; DELAYED-ACTION PREPARATIONS; DRUG DOSAGE CALCULATIONS; FEMALE; FENTANYL; HUMANS; MALE; METHADONE; MIDDLE AGED; MORPHINE; NEOPLASMS; OXYCODONE; PAIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 67650641512     PISSN: 15360288     EISSN: 15360539     Source Type: Journal    
DOI: 10.1080/15360280802537241     Document Type: Article

References (33)

1. World Health Organization. Cancer Pain Relief, 2nd ed. Geneva, Switzerland: World Health Organization; 1996.
2. Pereira J, Lawlor P, Vigano A, Dorgan M, Bruera E. Equianalgesic dose ratios for opioids: a critical review and proposals for long-term dosing. J Pain Symptom Manage. 2001;22:672-687.
3. Anderson R, Saiers JH, Abram S, Schlicht C. Accuracy in equianalgesic dosing: conversion dilemmas. J Pain Symptom Manage. 2001;21:397-406.
4. Patanwala AE, Duby J, Waters D, Erstad BL. Opioid conversions in acute care. Ann Pharmacother. 2007;41:255-267.
5. Gammaitoni AR, Fine P, Alvarez N, McPherson ML, Bergmark S. Clinical application of opioid equianalgesic data. Clin J Pain. 2003;19:286-297.
6. Ripamonti C, Groff L, Brunelli C, Polastri D, Stavrakis A, De Conno F. Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio? J Clin Oncol. 1998;16:3216-3221.
7. Jacox A, Carr DB, Payne R, et al. Management of cancer pain. Clinical practice guidelines No. 9. AHCPR Publication No 94-0592. Rockville, MD: Agency for Health Care Policy and Research, U.S. Department of Health and Human Services, Public Health Service, 1994.
8. Duragesic Prescribing Information. Titusville, NJ: Janssen Pharmaceutica Products, L.P., February 2005.
9. Epocrates Tables: Opioid Equivalents. Epocrates Essentials Version 1.0. Epocrates, Inc. 2003-2007. San Mateo, CA., 2007.
10. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Center for Cancer Pain Research's opioid conversion program. http://www.hopweb.org/. Accessed September 4, 2007.
11. Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain, 5th ed. Glenview, IL: American Pain Society; 2003.
12. Nissen LM, Tett SE, Cramond T, Williams B, Smith MT. Opioid analgesic prescribing and use - an audit of analgesic prescribing by general practitioners and The Multidisciplinary Pain Centre at Royal Brisbane Hospital. Br J Clin Pharmacol. 2001;52:693-698.
13. Post-White J, Kinney ME, Savik K, et al. Therapeutic massage and healing touch improve symptoms in cancer. Integr Cancer Ther. 2003;2:332-344.
14. Wilkie DJ, Kampbell J,CutshallS, et al. Effects of massage on pain intensity, analgesics and quality of life in patients with cancer pain: a pilot study of a randomized clinical trial conducted within hospice care delivery. Hospice J. 2000;15:31-53.
15. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med. 1994;23:129-138.
16. Galer BS, Jensen MP. Development and preliminary validation of a pain measure specific to neuropathic pain: The Neuropathic Pain Scale. Neurology. 1997;48:332-338.
17. Jensen TS, Gottrup H, Sindrup SH, Bach FW. The clinical picture of neuropathic pain. Eur J Pharmacol. 2001;429:1-11.
18. Donner B, Zenz M. Transdermal fentanyl: a new step on the therapeutic ladder. Anticancer Drugs. 1995;6(Suppl 3):39-43.
19. Foley KM, Houde RW. Methadone in cancer pain management: individualize dose and titrate to effect. J Clin Oncol. 1998;16:3213-3215.
20. Beaver WT, Wallenstein SL, Rogers A, Houde RW. Analgesic studies of codeine and oxycodone in patients with cancer. II. Comparisons of intramuscular oxycodone with intramuscular morphine and codeine. J Pharmacol Exp Ther. 1978;207:101-108.
21. Sawe J, Dahlstrom B, Paalzow L, Rane A. Morphine kinetics in cancer patients. Clin Pharmacol Ther. 1981;30:629-635.
22. Donner B, Zenz M, Tryba M, Strumpf M. Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain. Pain. 1996;64:527-534.
23. AhmedzaiS,BrooksD.Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group. J Pain Symptom Manage. 1997;13:254-261.
24. Watanabe S, Pereira J, Hanson J, Bruera E. Fentanyl by continuous subcutaneous infusion for the management of cancer pain: a retrospective study. J Pain Symptom Manage. 1998;16:323-326.
25. Lawlor PG, Turner KS, Hanson J, Bruera ED. Dose ratio between morphine and methadone in patients with cancer pain: a retrospective study. Cancer. 1998;82:1167-1173.
26. Mercadante S, Casuccio A, Fulfaro F, Groff L, Boffi R, Villari P, Gebbia V, Ripamonti C. Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. J Clin Oncol. 2001;19:2898-2904.
27. Tse DM, Sham MM, Ng DK, Ma HM. An ad libitum schedule for conversion of morphine to methadone in advanced cancer patients: an open uncontrolled prospective study in a Chinese population. Palliat Med. 2003;17:206-211.
28. Bruera E, Palmer JL, Bosnjak S, Rico MA, Moyano J, Sweeney C, Strasser F, et al. Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study. J Clin Oncol. 2004;22:185-192.
29. Heiskanen T, Kalso E. Controlled-release oxy-codone and morphine in cancer related pain. Pain. 1997;73:37-45.
30. Bruera E, Belzile M, Pituskin E, Fainsinger R, Darke A, Harsanyi Z, et al. Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain. J Clin Oncol. 1998;16:3222-3229.
31. Lauretti GR, Oliveira GM, Pereira NL. Comparison of sustained-release morphine with sustained-release oxycodone in advanced cancer patients. Br J Cancer. 2003;89:2027-2030.
32. Stamer UM, Stüber F. Genetic factors in pain and its treatment. Curr Opin Anaesthesiol. 2007;20:478-484.
33. Cleary JF. The pharmacologic management of cancer pain. J Palliat Med. 2007;10:1369-1394.